Qualcomm and Vivus released their latest earnings reports after closing bell tonight. Qualcomm reported adjusted earnings of 91 cents per share or $1.4 billion and $5.5 billion in revenue for its fourth fiscal quarter. Analysts had wanted to see earnings of 86 cents per share and $5.21 billion in revenue. In last year’s fourth quarter, the chip maker reported earnings of $1.26 per share or $2.1 billion and $6 billion in revenue.
Vivus posted losses of 15 cents per share and $24.9 million in revenues. Wall Street was looking for losses of 17 cents per share and $20.24 million in revenue. In last year’s third quarter, Vivus reported losses of 10 cents per share and $33.9 million in revenue.
Qualcomm shares edge downward
Qualcomm’s GAAP earnings were 67 cents per share or $1.1 billion, compared to last year’s net income of $1.9 billion or $1.11 per share. The chip maker’s full year revenues for 2015 were $25.3 billion, while non-GAAP earnings for the full year were $4.66 per share or $7.6 billion and GAAP earnings were $3.22 per share or $5.3 billion.
The company shipped 203 million MSM chips during the quarter, a decline of 236 million in last year’s fourth quarter. Total reported device sales increased to 58.3 million, while 3G/ 4G device shipments climbed to a range of 276 million to 280 million. The average selling price of 3G/ 4G devices was between $207 and $213.
Qualcomm announced that it’s changing the way it provides guidance and will no longer provide annual guides for revenue and earnings. Management did say they expect $5.2 billion to $6 billion in revenues for the current quarter and non-GAAP earnings of 80 cents to 90 cents per share, both of which would mark declines from last year. They expect GAAP earnings to fall to between 80 cents and 90 cents per share as well. Management expects to ship between 225 million and 245 million MSM chips during the current quarter.
The chip maker bought back 59 million shares during the fourth quarter and paid out dividends of 48 cents per share.
Qualcomm shares slipped by as much as 0.1% to $60.20 per share in after-hours trades.
Vivus’ loss not as bad as expected
Vivus said net product revenue for Qsymia sales climbed from $12.45 million last year to $14 million this year. Supply revenue for the company’s commercialization agreements for Stendra and Spendra nearly doubled to $10.01 million, and royalty revenue fell to $869,000. The company reported that about 146,000 Qsumia prescriptions were dispensed in the current quarter, compared to 140,000 in last year’s third quarter.
Shares of Vivus edged slightly higher to $1.57 per share after tonight’s earnings report.
